Radiologic–Pathologic Correlation of Hepatocellular Carcinoma Treated with Chemoembolization
- 5 December 2009
- journal article
- research article
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 33 (6), 1143-1152
- https://doi.org/10.1007/s00270-009-9766-5
Abstract
To correlate posttreatment radiologic and pathologic findings in patients who underwent transarterial chemoembolization before transplantation or resection. Thirty-five patients with postchemoembolization follow-up imaging underwent liver transplantation/resection. Pre- and posttreatment contrast-enhanced magnetic resonance imaging were used to evaluate radiologic findings. Imaging characteristics using World Health Organization (WHO) and European Association for the Study of the Liver (EASL) criteria after treatment were evaluated. Treated lesions were examined by pathology (gold standard) for the assessment of necrosis. Radiologic findings on magnetic resonance imaging were correlated to pathologic findings to assess the predictability by imaging of actual necrosis. Kappa (κ) statistics were used to determine intermethod agreement between WHO and EASL criteria. Fourteen (40%) of 35 lesions had biopsy-proven hepatocellular carcinoma. Thirteen (37%) of 35 target lesions showed complete pathologic necrosis. Complete pathologic necrosis was seen in 35% of lesions with pretreatment size <3 cm. Complete pathologic necrosis was seen in 1 (100%) of 1, 6 (67%) of 9, 6 (33%) of 18, and 0 (0%) of 7 of the lesions that exhibited complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) by WHO criteria, respectively. Complete pathologic necrosis was seen in 9 (82%) of 11, 4 (36%) of 11, 0 (0%) of 8, and 0 (0%) of 5 of the lesions that showed CR, PR, SD, or PD by EASL criteria, respectively. EASL CR and WHO response were shown to have ≥85% specificity for predicting complete pathologic necrosis. The κ coefficient for agreement between WHO and EASL was 0.29. EASL and WHO criteria had minimal intermethod agreement. EASL CR and WHO response were able to predict pathologic necrosis.Keywords
This publication has 33 references indexed in Scilit:
- Radiologic–pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres #Hepatology, 2009
- Evaluation of tumor response after locoregional therapies in hepatocellular carcinomaCancer, 2009
- Radioembolization with Yttrium-90 Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver MalignanciesJournal of Vascular and Interventional Radiology, 2006
- Management of Hepatocellular Carcinoma *Hepatology, 2005
- Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation†Hepatology, 2005
- Hepatocellular carcinoma and hepatitis C in the United StatesHepatology, 2002
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Pathologic Characteristics of Hepatocellular CarcinomaSeminars in Liver Disease, 1986